Dr. Hu’s project will focus on developing more effective curative therapies to manage ovarian cancer as a chronic disease. The approach Dr. Hu will take will be examining the growth inhibitory effects of manumycin, a natural product derived from the bacteria streptomyces, alone and in combination with paclitaxel (Taxol). Dr. Hu hypothesizes that manumycin could inhibit ovarian tumor cell growth, and in addition this study will also examine the synergistic relationship between manumycin and palcitaxel.
Wei Hu, M.D., Ph.D. has been with M.D. Anderson since 1994. She is currently an Assistant Professor in the Department of Gynecologic Oncology at MDACC. Dr.Hu received her Medical degree in 1986 and gained her Ph.D. in 1993 at the Tongii Medical University, Huazhong University of Science and Technology. She received her Postdoctoral training during the period of 1994-1997 at the University of Texas M.D. Anderson Cancer Center in the Department Gynecologic Oncology and Cellular Oncology.
Dr. Hu’s main research interests have focused on the areas of targeting epigenetic abnormalities and tumor environment in VEGF-resistant ovarian cancer, and RNA interference based-treatment. Dr. Hu is the principal and co-investigator for several translational and preclinical studies which have been supported by peer-reviewed resources and private industries. She has published numerous peer-reviewed and invited review articles and co-authored for several book chapters. In 2009, she began collaborating with Dr. Anil K Sood on various basic and translational projects and she has been under his direct supervision. She has several joint publications with Dr. Sood and she functions as a Co-Investigator with him on several funded projects.
Dr. Hu serves on the editorial board for several journals and has been a reviewer for journals. She is an Adjunct Faculty Member at The University of Texas Graduate School of Biomedical Sciences at Houston. She is an active member of American Association of Cancer Research, International Gynecology of Cancer Society, and American Society of Clinical Oncology.